AA
NVO

Advisory Alpha’s Novo Nordisk NVO Stock Holding History

Advisory Alpha’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-48
Closed -$1.24K – 874
2019
Q3 		$1.24K Buy
+48
New +$1.21K ﹤0.01% 708
2019
Q2 		– Sell
-48
Closed -$1.16K – 466
2019
Q1 		$1.16K Buy
+48
New +$1.18K ﹤0.01% 588

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $7.77B AUM 9.43% 1-Year Est. Return

Advisory Alpha's NVO Position: Q4 2019 in Review

Advisory Alpha sold out of Novo Nordisk (NVO) in Q4 2019, closing a stake of 48 shares — an estimated $1.24K sold.

Advisory Alpha first reported a position in NVO in Q1 2019 and held it in 2 quarters. The position peaked at $1.24K in Q3 2019. 640 funds tracked by Wall St. Rank hold NVO as of Q4 2019.

  • Advisory Alpha reported no remaining Novo Nordisk position as of Q4 2019 after selling out during the quarter.
  • Advisory Alpha sold 48 Novo Nordisk shares in Q4 2019, an estimated $1.24K.
  • Advisory Alpha first reported a position in Novo Nordisk in Q1 2019 and held it in 2 quarters.
  • Advisory Alpha's Novo Nordisk position peaked at $1.24K in Q3 2019.
  • 640 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2019.

Based on Advisory Alpha's 13F filing for Q4 2019, filed 14 Feb 2020.